Checkpoint Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	2016 - 2020
Operating Revenue	41,833	41,508	40,261	37,489	34,418	33,604	Upgrade
Other Revenue	397.3	397.3	362.43	226	145.56	78.83	Upgrade
Revenue	42,231	41,906	40,624	37,715	34,563	33,683	Upgrade
Revenue Growth (YoY)	3.20%	3.16%	7.71%	9.12%	2.61%	-4.97%	Upgrade
Cost of Revenue	28,137	28,006	27,468	25,686	23,969	22,555	Upgrade
Gross Profit	14,094	13,899	13,156	12,028	10,595	11,128	Upgrade
Selling, General & Admin	7,723	7,806	8,066	7,584	6,591	6,969	Upgrade
Research & Development	1,659	1,426	1,271	1,016	979.64	926.73	Upgrade
Other Operating Expenses	243.69	214.72	203.41	205.31	176.11	184.37	Upgrade
Operating Expenses	9,738	9,558	9,566	8,873	7,788	8,103	Upgrade
Operating Income	4,356	4,341	3,590	3,155	2,806	3,025	Upgrade
Interest Expense	-99.82	-96.95	-114.91	-120.04	-68.48	-68.64	Upgrade
Interest & Investment Income	107.4	104	94.05	103.35	80.4	60.99	Upgrade
Currency Exchange Gain (Loss)	-2.56	-2.56	-1.04	-34.7	-2.27	-10.04	Upgrade
Other Non Operating Income (Expenses)	-58.15	-27.16	-29.65	-27.16	-31.93	-16.68	Upgrade
EBT Excluding Unusual Items	4,303	4,318	3,538	3,076	2,784	2,990	Upgrade
Impairment of Goodwill	-	-	-	-	-2.92	-	Upgrade
Gain (Loss) on Sale of Investments	-124.63	-129.19	-233.47	-113.09	-96.31	-27.53	Upgrade
Gain (Loss) on Sale of Assets	-21.53	-5.46	4.32	8.26	-0.03	322.64	Upgrade
Asset Writedown	-25.19	-25.19	-5.14	-5.87	-5.09	-2.51	Upgrade
Other Unusual Items	206.56	143.19	161.87	65.6	147.89	170.41	Upgrade
Pretax Income	4,338	4,302	3,466	3,031	2,828	3,453	Upgrade
Income Tax Expense	790.35	807.33	619.59	498.5	488.91	543.67	Upgrade
Earnings From Continuing Operations	3,548	3,494	2,846	2,533	2,339	2,910	Upgrade
Minority Interest in Earnings	16.48	17.92	-7.54	-33.41	-37	-89.86	Upgrade
Net Income	3,564	3,512	2,839	2,499	2,302	2,820	Upgrade
Net Income to Common	3,564	3,512	2,839	2,499	2,302	2,820	Upgrade
Net Income Growth	20.99%	23.71%	13.59%	8.58%	-18.38%	0.24%	Upgrade
Shares Outstanding (Basic)	1,752	1,752	1,750	1,750	1,750	1,750	Upgrade
Shares Outstanding (Diluted)	1,754	1,753	1,752	1,750	1,750	1,750	Upgrade
Shares Change (YoY)	0.15%	0.08%	0.10%	0.00%	-0.00%	0.00%	Upgrade
EPS (Basic)	2.03	2.00	1.62	1.43	1.32	1.61	Upgrade
EPS (Diluted)	2.03	2.00	1.62	1.43	1.32	1.61	Upgrade
EPS Growth	20.81%	23.61%	13.47%	8.58%	-18.37%	0.24%	Upgrade
Free Cash Flow	1,508	2,021	2,323	1,189	2,351	1,938	Upgrade
Free Cash Flow Per Share	0.86	1.15	1.33	0.68	1.34	1.11	Upgrade
Dividend Per Share	0.930	0.930	0.580	0.290	0.290	0.230	Upgrade
Dividend Growth	60.35%	60.35%	100.00%	-	26.09%	-17.86%	Upgrade
Gross Margin	33.37%	33.17%	32.38%	31.89%	30.65%	33.04%	Upgrade
Operating Margin	10.32%	10.36%	8.84%	8.37%	8.12%	8.98%	Upgrade
Profit Margin	8.44%	8.38%	6.99%	6.63%	6.66%	8.37%	Upgrade
Free Cash Flow Margin	3.57%	4.82%	5.72%	3.15%	6.80%	5.75%	Upgrade
EBITDA	5,112	5,091	4,318	3,778	3,316	3,456	Upgrade
EBITDA Margin	12.11%	12.15%	10.63%	10.02%	9.59%	10.26%	Upgrade
D&A For EBITDA	755.77	750.15	727.64	622.73	509.65	431	Upgrade
EBIT	4,356	4,341	3,590	3,155	2,806	3,025	Upgrade
EBIT Margin	10.32%	10.36%	8.84%	8.37%	8.12%	8.98%	Upgrade
Effective Tax Rate	18.22%	18.77%	17.88%	16.45%	17.29%	15.74%	Upgrade
Revenue as Reported	42,231	41,906	40,624	37,715	34,563	33,683	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.